Improving treatment for neonatal seizures using Levetiracetam
NEOLEV3: A Phase IIb Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures of Mild to Moderate Severity IND-109622 (September 6, 2020)
This study is looking at how a safer medication called Levetiracetam can help treat mild to moderate seizures in newborns, with the hope of improving their long-term brain development and reducing side effects from older treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10708735 on NIH RePORTER |
What this research studies
This research aims to enhance the treatment of neonatal seizures, which affect 1 in 300 infants and can lead to serious long-term disabilities. The study will explore the use of Levetiracetam, a safer anticonvulsant medication, to reduce the burden of mild to moderate seizures in neonates. By conducting a dose escalation and safety study, researchers will determine the maximum tolerated dose of Levetiracetam while minimizing side effects associated with traditional treatments like phenobarbital. The goal is to improve long-term neurodevelopmental outcomes for affected infants.
Who could benefit from this research
Good fit: Ideal candidates for this research are neonates experiencing mild to moderate seizures.
Not a fit: Patients with severe neonatal seizures may not benefit from this research as they may require different treatment approaches.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatment options for neonatal seizures, potentially reducing the risk of long-term disabilities.
How similar studies have performed: Previous studies have shown promise in using Levetiracetam for seizure control, indicating potential for success in this approach.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Wang, Sonya Grace — University of Minnesota
- Study coordinator: Wang, Sonya Grace
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.